# Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer

> **NCT01843062** · PHASE3 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 233 (actual)

## Conditions studied

- Differentiated Thyroid Cancer

## Interventions

- **DRUG:** Selumetinib
- **DRUG:** Placebo
- **DRUG:** Radioactive Iodine Therapy

## Key facts

- **NCT ID:** NCT01843062
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-08-27
- **Primary completion:** 2018-05-18
- **Final completion:** 2019-03-06
- **Target enrollment:** 233 (ACTUAL)
- **Why stopped:** Study was terminated based on the findings of primary analysis at 18 months post-RAI treatment. Patients pending 3 year follow up had end of study phone call.
- **Last updated:** 2019-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01843062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01843062, "Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01843062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*